Podcasts about bellus

Wes and Nick watch this 50s Sci-Fi Doomsday Classic with a lot of scienciy babble building and transatlantic talking spells involving Planets coming out of nowhere. Plot:South African pilot Dave Randall serves as courier - transporting a briefcase to American scientist, Dr Hendron. Inside the case are documents which state the star Bellus will collide with Earth, destroying it. A plan is developed to build a spaceship to carry a select few to the planet Zyra, a planet orbiting Bellus.Support the show:

The topics, stocks and shares mentioned/discussed include: Plans for Twin Petes Investing podcast 100 Triple Point Social Housing REIT / SOHO Wood Group / WG. Avacta / AVCT THG Plc / THG / Takeover ? GSK Plc / GSK Haleon / HLN Decha Pharma / DPH Network International Holdings / NETW Pfizer / PFE Seagen / SGEN Bellus Health / BLU Merck & Co / MRK Prometheus Biosciences / RXDX KAPE Watkins Jones / WJG Nominee action / Shareholder rights petition Global Global Elite Companies Top 10 FTSE 100 Aim All-Share Nasdaq Nikkei Index CAC 40 Takeovers Psychology / Fixed mindset / Bias Harriman House books Powder Monkey Brewing Co 5% discount code : TWINPETES Menphys Charity Appeal please make a donation on the TwinPetes Investing Challenge 2023 Just Giving Page Master Investor Show 2023 / Investing Matters panel session UK Investor Show on 13th May. Will you be attending? Investing Trading & much more The Twin Petes Challenge 2023 / Charity fundraise for the MENPHYS Charity. Have you enjoyed one or more of these podcasts. Yes . Then please make a donation , every pound will help. JUST GIVING TWIN PETES FUNDRAISING FOR THE MENPHYS CHARITY https://www.justgiving.com/fundraising/twinpeteschallenge23 Thank you. The Twin Petes Investing podcasts will be linked to and written about on the Conkers3 website and also on the WheelieDealer website . Thank you for reading this article and listening to this podcast, we hope you enjoyed it. Please share this article with others that you know will find it of interest. PLEASE SUBSCRIBE TO THE TWIN PETES INVESTING PLATFORM THAT YOU ARE LISTENING TO THIS PODCAST ON. THANK YOU.

2022 was the third straight year where the coronavirus pandemic had an extreme effect on the revenue of several biopharma companies. Pfizer became the first company in industry history to rack up more than 100 billion dollars in sales. We discuss how other companies fared in 2022 and what we can expect this year.  To learn more about the topics in this episode:  The top 20 pharma companies by 2022 revenue Big Pharmas finally strike with GSK, Merck acquisitions, signaling accelerating pace of M&A Merck & Co. inks $11B Prometheus takeover, firing starting gun on race for blockbuster bowel market GSK coughs up $2B to buy Bellus for late-phase rival to Merck & Co.'s stuttering gefapixant Medtronic embarks on monthslong global layoffs, with total cuts unknown Eli Lilly adds $1.6B to its manufacturing spending plan in Indiana, breaking a company record J&J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma, leaked abstract shows The Top Line is produced by senior podcast producer Teresa Carey. The stories are by all our "Fierce" journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

L'essentiel des nouvelles économiques, technologiques et financières[texte ni révisé ni corrigé à des fins de publication]L'inflation descend sous la barre des 5%Le taux annuel d'inflation au Canada a été de 4,3% en mars. C'est un ralentissement notable par rapport aux 5,2% enregistrés en février et 5,9% en janvier. C'est aussi le plus bas taux d'inflation depuis août 2021.Ce ralentissement s'explique en partie par le fait que, en mars, la comparaison annuelle des prix se faisait avec mars 2022.Or, ce mois correspondait au déclenchement de la guerre en Ukraine, qui avait fait grimper les prix d'un coup.L'entreprise techno montréalaise Nuvei est à nouveau attaquée par Le vendeur à découvert américain Spruce Point Capital ManagementDans un rapport d'analyse, Spruce Point accuse Nuvei d'avoir caché plusieurs choses ‒ notamment le fait que Nuvei avait un partenariat avec le service d'échange de cryptomonnaie FTX, qui a fait faillite à la fin de l'an dernier.C'est la deuxième fois en 16 mois que Spruce Point parie sur une chute de l'action de Nuvei. En décembre 2021, Spruce avait publié un premier rapport, accusant alors Nuvei de mener des activités frauduleuses et d'avoir des liens avec l'industrie du film pour adultes.Bellus Santé, une entreprise biopharmaceutique de Laval, est achetée par le géant britannique GSK pour environ 2 milliards $US. La transaction permet à GSK de mettre la main sur un traitement de la toux chronique. 28 millions de personnes dans le monde souffrent de toux chronique.Bellus est dirigée par Roberto Bellini, qui est le fils de Francesco Bellini.En 2001, Francesco Bellini avait vendu une autre société pharmaceutique, BioChem Pharma, pour presque 6 milliards $.Galen Weston, qui a figuré dans plusieurs annonces publicitaires de la marque le Choix du Président, ne sera plus président de Loblaw au début de l'an prochain. Il quitte la direction au quotidien de l'entreprise et sera remplacé dans son rôle de président par Per Bank, qui est actuellement chef de la direction de Salling Group, un conglomérat danois de vente au détail.Galen Weston conservera cependant son rôle de président du conseil d'administration de Loblaw, et il restera président et chef de la direction de George Weston, la société mère de Loblaw.Aux États-Unis, la chaine américaine Fox News et le fabricant de machines de vote électronique Dominion Voting Systems ont trouvé hier un accord de dernière minute, alors qu'allait débuter un procès en diffamation de la chaine. Fox News versera presque 788 millions $US à Dominion.Dominion lui demandait 1,6 milliard $US. L'entente hors cours est donc pour environ la moitié de ce montant.---Détails sur ces nouvelles et d'autres nouvelles: https://infobref.com.S'abonner aux infolettres gratuites d'InfoBref: https://infobref.com/infolettres_Écouter les balados d'InfoBref: https://infobref.com/audio[Découvrez Actualités InfoBref, un balado quotidien des principales nouvelles générales, parfaitement complémentaire d'InfoBref Affaires]Voir notre épisode hebdo «à retenir cette semaine»: https://www.youtube.com/@infobrefCommentaires et suggestions à l'animateur Patrick Pierra, ou pour commanditer nos balados: editeur@infobref.com Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Alex is a professional photographer specializing in creating automotive-focused commercial, editorial, and lifestyle images. As a lifelong car enthusiast, he has dedicated his life to everything on four wheels.

Shelby Evans is the owner of Beyond Bellus in Kerrville! Shelby was voted Best of Kerrville, 2021 - Best Skin Care Specialist Aesthetician. They do facials, lashes extensions, body waxing and facials, body treatments, brow shaping, and more. Shelby gives great insight into mindset and affirmations!

TSN edge contributor Luke Bellus joins the show to preview the Monday nighter, Talk all season long award markets, and what is going on in the AFC

Joey Bellus joins Andrew Nauenburg and Zac Dominguez. Joey runs optimal performance training in Mesa, AZ. His education and training systems are built on evidence-based research and best practices in exercise science, meditation, and personal growth. He works with all sorts of athletes from MMA to MLB and so on. What you'll really like about Joey is how he never hesitates to think outside the box or try new things to help the individual athlete. He's got his own podcast, the Joey B show, check it out: Full show notes: heycoachpodcast.com/joey

Beauty Changes Lives, a nonprofit founded in 2013, is geared to equip and empower the next generation of beauty professionals, including estheticians. In today's episode of ASCP Esty Talk we are joined by Beauty Changes Lives founder Lynelle Lynch to discuss how she's engaged many of the skin care industry's elite brands and influencers to support esthetic and spa education.   Innovator. Trailblazer. Disruptor of the status quo. Bellus Academy owner Lynelle Lynch has fearlessly redefined beauty education in America. Within a decade of taking the leadership reins at Bellus Academy, Lynelle led her team to become North America's number-one beauty academy according to Intercoiffure. Bellus has since emerged as a destination academy attracting students from around the globe. As an advocate for education, humanitarian service, and the professional beauty industry, Lynelle's record of accomplishments continues to grow. Bellus Academy has been honored with multiple Excellence in Education Awards presented by Modern Salon and was the first beauty school in the US to offer the prestigious CIDESCO Skincare certificate. Along the way, Lynelle's passion for humanitarian leadership earned Bellus Academy recognition as America's first school to offer the Wellness for Cancer credential and two consecutive Excellence in Community Service Awards, California's highest honor for community service in the education sector. She is also the founder of Beauty Changes Lives, a nonprofit designed to equip and empower beauty professionals.   Beauty Changes Lives www.Beautychangeslives.org www.facebook.com/BeautyChangesLives www.instagram.com/beautychangeslives   Make Your Mark Campaign itstimetomakeyourmark.com   Bellus Academy www.Bellusacademy.edu www.instagram.com/bellusacademy www.facebook.com/bellusacademy   About our Sponsor: LAMPROBE:   The popular and revolutionary LAMPROBE utilizes radio and high-frequency technology to treat a wide variety of Minor Skin Irregularities™ (MSI)—non-invasively—with instantaneous results. Common conditions treated by the LAMPROBE include: vascular MSI, such as cherry angiomas; dilated capillaries; sebaceous MSI, including cholesterol deposits and milia; and hyperkerantinized MSI, such as keratoses and skin tags.     The LAMPROBE uniquely assists modern, capable, and skilled skin care practitioners to do their work more effectively and with greater client and professional satisfaction. Setting standards in quality, education, and training, the LAMPROBE has become an essential tool enabling skin care practitioners around the world to offer new revenue-enhancing and highly in-demand services.   Website: www.lamprobe.com   Email: info@lamskin.com   Phone: 877-760-2722   Instagram: www.instagram.com/lamprobe   Facebook: www.facebook.com/theLAMPROBE   About our sponsor NeoGenesis:   Introducing the next generation of stem cell science for skin and hair care: NeoGenesis patented S²RM® technology. This exclusive technology harnesses the power of adult stem cell-released molecules to awaken your body's natural regenerative power. This natural approach to healing simply returns to the damaged tissue the molecules that were present when the skin was young and healthy. Because of what we are able to do with traumatic wound care—from accidents, burns, chemo, radiation, and more—we knew this science could also serve aging concerns and chronic issues. We also enhance the result of all treatment-room modalities, reduce downtime, and aid in resolving issues resulting from treatment modalities that did not go exactly as planned. There are no contraindications, and we offer a full money-back guarantee on our skin care products.    YOUTUBE    INSTAGRAM    FACEBOOK    About our sponsor NMSWP:   Meet Toshiana Baker, the founder of NMSWP. Toshiana is a licensed esthetician who grew into an international educator, traveling globally to facilitate spa and beauty-related programs that she created. At one time, she led a team of 250+ estheticians nationally as the Director of Esthetics for an iconic luxury  spa chain with over 30 locations. She was also the Regional Operations Director of four full-service spa/salons, including two inside of Saks Fifth Avenue and the Education Executive for the iconic brow artistry brand Anastasia Beverly Hills. Toshiana also held positions of leadership at other luxury influencer brands in spa, cosmetics, and retail. In 2016, she left the corporate space to become a full-time entrepreneur who parlays her wealth of experience to help small business owners, solo practitioners and independent brands grow and scale. Seeing a gap in the spa and wellness space for support, professional development, resources, and education for those of diverse backgrounds, she founded the Network of Multicultural Spa and Wellness Professionals (NMSWP) to be the gap filler. More than that, she wanted to create a community that feels like a “tribe to thrive” and to be a beacon of light and excellence for the spa and wellness industry.     Online: www.nmswp.com   Email: hello@nmswp.com   Instagram: @WeAreNMSWP    Facebook: https://www.facebook.com/WeAreNMSWP   About Associated Skin Care Professionals (ASCP):   Associated Skin Care Professionals (ASCP) is the nation's largest association for skin care professionals and your ONLY all-inclusive source for professional liability insurance, education, community, and career support. For estheticians at every stage of the journey, ASCP is your essential partner. Get in touch with us today if you have any questions or would like to join and become an ASCP member.   Connect with ASCP:   Website: www.ascpskincare.com   Email: getconnected@ascpskincare.com   Phone: 800-789-0411   Facebook: www.facebook.com/ASCPskincare   Instagram: www.instagram.com/ascpskincare  

Kiteljesedés, vágyak megélése anyaként Vajon létezik olyan kapcsolat, ahol a férfi és a nő is, gyerekek mellett, ki tud teljesedni, meg tudja élni az álmait, vágyait? Vagy egyik fél mindig többet áldoz fel? A vírus helyzettel egyre nőtt a szakadék a "terheket" illetően, hogyan lehet ezek mellett egy harmonikus család modellt működtetni? A mai adásban a megszokott őszinteséggel beszélgetünk a fenti a mindennapokat erősen érintő, sokszor igen húsbavágó, kérdésekről sztárvendegünkkel Bellával.♥️ Special Guest: Bellus.

Joey Bellus has gathered many tools and insights through his education, but most importantly through his personal successes and failures. In this episode, Joey, who is of Native American descent, shares how his learning from the Process helped him lay the foundation for his practice of understanding his Native traditions. Listen in as Joey shares about traditions, race, and finding and living his life purpose. Joey also tells about his experience with Hoffman's new Virtual Graduate Intensive. Joey has found the courage to heal from addiction, trauma, depression, and anxiety. Through all of this, he has discovered meaning and purpose in his life. Joey aims to share his purpose with as many people as possible while on this planet. Using fitness, nutrition, and meditation, he helps people create positive habits to organize and structure their lives in a way that facilitates positive transformation. You can read more about Joey and his work here. Subscribe on iTunes

This week on Episode of 240 of the Inner Monologue is owner and operator of Optimal Performance Training. Optimal Performance Training studio acts as a mirror. It is a place where you go to face yourself, your fears, your doubts, your failures. The four walls of the studio house your growth: where you came from, and where you’re going; from whom you were, to who you are working to become. Joey and I talk about his journey that lead him to open Optimal Performance Training. It is a Journey of loss, abuse, discovery and transcendence. To learn more about Joey & Optimal Performance Training go to... www.Optimalaz.com Entelechy Visions www.entelechyvisions.com Theme Music provided by Cloudkicker.   To learn more go to www.cloudkickermusic.com Other Musical Contributions The Slow Dancing Society https://slowdancingsociety.bandcamp.com Hidden Shoal http://www.hiddenshoal.com/project/slow-dancing-society/ Subscribe to Inner Monologue today on iTunes, Spotify, Stitcher or I Heart Radio!

Els serveis de policia de Perpinyà han descobert més de 360 plantes de marihuana a la cité Bellus. Dues plantacions van ser trobades durant una operació policial realitzada divendres passat. Una investigació policia ha estat oberta contra un antic professor del Conservatori de Perpinyà per agressions sexuals sobre menors. El Conservatori està preparant una reunió d’informació dirigida a les famílies. Avui sem el 3 de desembre, dia internacional de les persones handicapades. Avui el secretari general de la direcció dels serveis departamentals de l’Educació Nacional delsbecatPirineus Orientals, Christian Horgues, visitarà el Pol Pediàtric del centre de cures de Cerdanya. Aquest any a l’Acadèmia de Montpeller hi ha 15 500 alumnes en situació d’hàndicap. Uns alumnes que reben l’ajuda d’acompanyants que els assisteixen al dia a dia a l’escola. Uns treballadors que denuncien una situació precària amb salaris inferiors als 800€ mensuals. Al Capcir l’obertura de les pistes d’esquí de Formiguera ha estat ajornada. Era prevista per demà dimecres, però les condicions meteorològiques ho impediran. Omnium Catalunya Nord comença, a partir d’avui, un nou cicle de cinema en català. El film que anirà voltant pels cinemes de Catalunya Nord aquest mes de desembre té com a protagonista Kilian Jornet. La Generalitat de Catalunya ha aprovat un Pla Director d'Urbanisme que redueix a la meitat els habitatges que es podien construir a la Costa Brava. Això vol dir que s'impedeix la construcció de 15.000 habitatges i es redueix en més de 1.000 hectàrees la superfície on es podria edificar.

Natalia Bellus brings scholarly insights into Robert Smith and his gothic, romantic inclinations to That Record Got Me High. We try and try to not look stupid, but alas, a lass does us in and gets the upper hand intellectually on Barry, and Jethro – which is Rob's real name. Disintegration will put you in a mood – to tease your dyed black hair, drink absinthe, and stand on cold deserted beaches. Support That Record Got Me High on Patreon: https://www.patreon.com/join/TRGMH? Thanks again to our bitchin' sponsor, http://isthistomorrow.com/

The regular practice of Stillness is an invaluable habit in our modern, progress-oriented lives. Besides its impact on physical, mental and spiritual health, Stillness is also important as a practice to maintain performance, connect to Gratitude, discover important messages and experience life. It is the space between the notes of life's music and, to find it, Joey recommends simply closing your eyes, taking 6 deep breaths and sitting still for 5 minutes at least once per day. You can also journal about your experience and discover what Stillness has to say to you.

Els professors i els pares d’alumnes del col·legi del Riberal de Sant Esteve van manifestar ahir davant la Inspecció Acadèmica. Protestaven contra el nombre d’alumnes massa elevat que hi haurà a les classes del col·legi a la propera reentrada. Divendres passat la rectora va refusar la creació de 3 classes suplementàries al col·legi del Riberal. Els professors alerten que el nombre d’alumnes podria pujar als 35 mainatges per classe, amb uns locals que no seran adaptats. Professors i pares d’alumnes anuncien que reprendran les protestes a la reentrada. Important operació antidroga al barri de l'Alt Vernet de Perpinyà. Dimarts la policia va desplegar nombrosos efectius a la cité Bellus. També van participar a l'operació els equips del RAID i els CRS. Els escorcolls van permetre descobrir mig quilo de cocaïna i 300 grams de cànnabis i marihuana. També es van trobar moltes armes de foc, 5 fusells i dues pistoles, així com 24 000 € en bitllets de banc. En total 8 persones van ser arrestades i plaçades en guàrdia a vista. Al vilatge de Sureda, un auxiliar de vida escolar de l'escola maternal és investigat per agressions sexuals sobre menors de 15 anys. 15 famílies han denunciat agressions sexuals sobre els seus fills. Es tracten de tocaments que s'haurien produït a partir del mes de febrer passat. L'home ha estat plaçat sota control judicial amb obligació d'instal·lar-se a fora del departament. Accident mortal ahir a Canet. Una dona de 70 anys va morir a inicis de tarda com a conseqüència d'un xoc frontal amb una altra votura a la D11. L'altra conductora, una dona de 60 anys i una nina de 11 anys van ser ferides de poca gravetat. La Comissió d'Interior del Parlament de Catalunya va aprovar ahir demanar la compareixença del ministre de l'Interior espanyol, Fernando Grande-Marlaska, i el seu antecessor, Juan Ignacio Zoido. Són sospitats d’haver presumptament ofert diners a una persona perquè infiltri la CUP per obtenir informacions sobre l'1-O, poc abans de referèndum. A Catalunya Nord han començat oficialment les rebaixes. Com és habitual a casa nostra les rebaixes comencen una setmana més tard que a la resta de l’estat. Això s’explica per la voluntat de fer coincidir el període de rebaixes amb la forta afluència turística. Les rebaixes a Catalunya Nord acabaran el dia 13 d’agost. A notar que a Catalunya Sud les rebaixes van començar el passat 1 de juliol i acabaran el 31 d’agost.

The AWESOME Chris Bellus from Laser Wolf and Invasive Species brewing in Fort Lauderdale joins us to introduce Rob and Barry to his favorite album, the debut by Chicago's Smashing Pumpkins, “Gish.” It's an album full of great textures and some sly nods to classic rock roots that might catch some listeners by surprise. https://invasivespeciesbrewing.com/# http://www.laserwolf.bar/home.html Support us on Patreon: https://www.patreon.com/TRGMH Support Is This Tomorrow?: http://isthistomorrow.com

[et_pb_section bb_built="1" specialty="off" _builder_version="3.17.4" background_image="https://kci.sendittoweb.com/wp-content/uploads/2018/10/1380x535_TheAsk_Hero.jpg" custom_padding="0px||0px|" custom_margin="0px||0px|" next_background_color="#ffffff" background_color="#333f48" module_class="trends-background"][et_pb_row _builder_version="3.17.2" make_fullwidth="on" use_custom_width="on" width_unit="off" custom_width_percent="100%" custom_margin="0px|||" custom_padding="0px||0px|" padding_top_1="0px" padding_bottom_1="0px" module_class="arrow-row"][et_pb_column type="4_4"][et_pb_code admin_label="Back Button" _builder_version="3.17.4" module_class="people-back" saved_tabs="all"]Back[/et_pb_code][/et_pb_column][/et_pb_row][et_pb_row _builder_version="3.17.2" background_color_1="#ffffff" custom_margin="0px||0px|" custom_padding="360px||0px|" padding_top_1="20px" padding_left_1="50px" use_custom_width="on" custom_width_px="1210px" custom_padding_last_edited="on|tablet" module_class="trends-header" custom_padding_tablet="160px||0px|"][et_pb_column type="1_2"][et_pb_text admin_label="EPISODE / 11" _builder_version="3.17.4" module_class="episode-number" custom_margin="||0px|"] EPISODE / 11 [/et_pb_text][et_pb_text admin_label="Immigrant/Diaspora Philanthropy" _builder_version="3.17.4" custom_margin="||20px|" module_class="trends-heading"] Immigrant/Diaspora Philanthropy [/et_pb_text][/et_pb_column][et_pb_column type="1_2"][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section bb_built="1" specialty="on" prev_background_color="#333f48" _builder_version="3.17.4" use_custom_width="on" width_unit="off" custom_width_percent="57%" custom_padding="0px|||" padding_top_2="0px" padding_top_1="45px"][et_pb_column type="3_4" specialty_columns="3"][et_pb_row_inner admin_label="Row" _builder_version="3.17.4" custom_margin="0px|||" custom_padding="0px|||" padding_top_1="0px" custom_padding_last_edited="off|"][et_pb_column_inner type="4_4" saved_specialty_column_type="3_4"][et_pb_post_title admin_label="Date - don't edit" _builder_version="3.17.4" title="off" author="off" date_format="M Y" categories="off" comments="off" featured_image="off" module_class="trends-date" custom_margin="||0px|" /][et_pb_text _builder_version="3.17.6"] [et_pb_section bb_built="1" specialty="off" _builder_version="3.17.4" background_image="https://kci.sendittoweb.com/wp-content/uploads/2018/10/1380x535_TheAsk_Hero.jpg" custom_padding="0px||0px|" custom_margin="0px||0px|" next_background_color="#ffffff" background_color="#333f48" module_class="trends-background"][et_pb_row _builder_version="3.17.2" make_fullwidth="on" use_custom_width="on" width_unit="off" custom_width_percent="100%" custom_margin="0px|||" custom_padding="0px||0px|" padding_top_1="0px" padding_bottom_1="0px" module_class="arrow-row"][et_pb_column type="4_4"][et_pb_code admin_label="Back Button" _builder_version="3.17.4" module_class="people-back" saved_tabs="all"]Back[/et_pb_code][/et_pb_column][/et_pb_row][et_pb_row _builder_version="3.17.2" background_color_1="#ffffff" custom_margin="0px||0px|" custom_padding="360px||0px|" padding_top_1="20px" padding_left_1="50px" use_custom_width="on" custom_width_px="1210px" custom_padding_last_edited="on|tablet" module_class="trends-header" custom_padding_tablet="160px||0px|"][et_pb_column type="1_2"][et_pb_text admin_label="EPISODE / 11" _builder_version="3.17.4" module_class="episode-number" custom_margin="||0px|"] EPISODE / 11 [/et_pb_text][et_pb_text admin_label="Immigrant/Diaspora Philanthropy" _builder_version="3.17.4" custom_margin="||20px|" module_class="trends-heading"] Immigrant/Diaspora Philanthropy [/et_pb_text][/et_pb_column][et_pb_column type="1_2"][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section bb_built="1" specialty="on" prev_background_color="#333f48" _builder_version="3.17.4" use_custom_width="on" width_unit="off" custom_width_percent="57%" custom_padding="0px|||" padding_top_2="0px" padding_top_1="45px"][et_pb_column type="3_4" specialty_columns="3"][et_pb_row_inner admin_label="Row" _builder_version="3.17.4" custom_margin="0px|||" custom_padding="0px|||" padding_top_1="0px" custom_padding_last_edited="off|"][et_pb_column_inner type="4_4" saved_specialty_column_type="3_4"][et_pb_post_title admin_label="Date - don't edit" _builder_version="3.17.4" title="off" author="off" date_format="M Y" categories="off" comments="off" featured_image="off" module_class="trends-date" custom_margin="||0px|" /][et_pb_text _builder_version="3.17.6"] Plane fragilis quadrupei imputat gulosus apparatus bellis. Bellus catelli divinus insectat rures, utcunque concubine libere senesceret adfabilis zothecas. Umbraculi corrumperet suis. Perspicax fiducias optimus verecunde praemuniet Medusa, et quadrupei aegre neglegenter senesceret oratori. Quadrupei agnascor adfabilis agricolae. Incredibiliter pretosius apparatus bellis iocari pessimus parsimonia syrtes. Suis deciperet lascivius fiducias, quamquam aegre gulosus cathedras comiter insectat plane perspicax concubine, iam chirographi suffragarit tremulus oratori. Octavius circumgrediet agricolae. Saburre deciperet concubine, etiam utilitas catelli iocari Pompeii. OSSIFRAGI FERMENTET SYRTES, UT OSSIFRAGI Umbraculi libere imputat chirographi, iam apparatus bellis insectat lascivius matrimonii. Augustus adquireret quinquennalis zothecas. Pompeii senesceret syrtes, quod adlaudabilis zothecas neglegenter conubium santet verecundus concubine. Aegre pretosius syrtes spinosus amputat saburre, utcunque umbraculi imputat agricolae. Umbraculi vocificat saetosus syrtes. [/et_pb_text][et_pb_text admin_label="Download PDF" _builder_version="3.17.4" module_class="download-pdf"] Transcript [/et_pb_text][/et_pb_column_inner][/et_pb_row_inner][/et_pb_column][et_pb_column type="1_4"][et_pb_image _builder_version="3.17.4" src="https://kci.sendittoweb.com/wp-content/uploads/2018/10/Episode_11_ASK_TILE.jpg" align="center" custom_margin="0px|||" custom_padding="0px|||" /][et_pb_code admin_label="Social Media Share" _builder_version="3.17.2" saved_tabs="all" global_module="777"][et_social_share_custom][/et_pb_code][et_pb_sidebar _builder_version="3.17.4" area="et_pb_widget_area_2" show_border="off" module_class="insights-sidebar" /][/et_pb_column][/et_pb_section] [/et_pb_text][et_pb_text admin_label="Download PDF" _builder_version="3.17.4" module_class="download-pdf"] Transcript [/et_pb_text][/et_pb_column_inner][/et_pb_row_inner][/et_pb_column][et_pb_column type="1_4"][et_pb_image _builder_version="3.17.4" src="https://kci.sendittoweb.com/wp-content/uploads/2018/10/Episode_11_ASK_TILE.jpg" align="center" custom_margin="0px|||" custom_padding="0px|||" /][et_pb_code admin_label="Social Media Share" _builder_version="3.17.2" saved_tabs="all" global_module="777"][et_social_share_custom][/et_pb_code][et_pb_sidebar _builder_version="3.17.4" area="et_pb_widget_area_2" show_border="off" module_class="insights-sidebar" /][/et_pb_column][/et_pb_section]

Interview with Personal Development Coach and motivational speaker Joey Bellus on the topic of transformation in everyday life. In this episode we examine what transformation means to him and how it plays out in his career, daily life and actions with the people around him.

Interview with Personal Development Coach Joey Bellus on his journey in creating his life as a motivational speaker and coach. 

Egyik kedves hallgatónk tanácsát megfogadtuk és összeült a csajos baráti társaság egy ízig vérig női epizód erejéig. Az év első adásában így ötösben beszélgetünk a nagy fogadalmakról, a kötelező szilveszteri bulikról és az év végi lezárásról! Hallgassátok szeretettel! Special Guests: Adrienn, Bellus, and Eszter.

is a woman possessed with success. Whether the task is staging at for or working harvest in Burgundy for she will achieve. Get this woman to a spin class in the morning and watch her run the world for the rest of the day.   Jordan joined us at in downtown Raleigh, North Carolina. Jordan was in NC to raise awareness for her creations and . While Jordan was here we took the opportunity to chat about what it’s like to work for and be the Director of Wine and Special Projects for . We also got behind the scenes of what it’s like to sit for the , be a mom and a somm and finally what High-Low means.   Listen to this episode to be inspired, awed and entertained. Jordan’s story is one of endless energy and drive plus intelligence and charm. Forget TED Talks, sit down with Jordan for about an hour.

Jordan Salcito has done it all! She has worked at the finest restaurants in NY, worked the harvest all over the world in including France, Italy and Patagonia. She founded Bellus wines, a collaboration with some of the world's top winemakers farming organically and has now introduced Ramona, a wine spritzer. We'll talk to Jordan about wine, spritzers, women in wine, social media, Momofuku and more. The Grape Nation is powered by Simplecast

Show Notes: In the news this week, the 2017 federal budget is out and we go one-on-one with BIOTECanada’s Andrew Casey to find out if it delivers on the promise of an Innovation Agenda, the NRC and the Centre for the Commercialization of Antibodies and Biologics (CCAB) colloborate on an antibody development initiative, and Bellus Health divests itself of Thallion Pharmaceuticals. We have all this and more coming up on Biotechnology Focus Radio. Welcome to another episode of Biotechnology Focus Radio. I’m your host Shawn Lawrence, here to give you a rundown of the week’s top stories on the Canadian biotech scene. Story 1 Our first story this week takes us to Vancouver, where Qu Biologics Inc. reports it has identified immune factors (cytokines and growth factors) in the blood of patients with Crohn’s disease that may predict response to its Site Specific Immunomodulators (SSIs) therapy. According to the company, SSIs are a unique platform of immunotherapies designed to restore the body’s innate immune system. Their discovery was made following further analysis of Qu Biologics recently completed Phase 2 Study in Crohn’s disease. The company says that when combined with patients’ clinical profiles, these biomarkers seemed to coorelate with identifying patients likely to respond to SSI treatment. Dr. Hal Gunn, CEO of Qu Biologics, explained these findings could  mean that patients with Crohn’s disease may now be closer to having precision treatment for their condition for the first time.  In addition, Qu Biologics’ Phase 2 randomized placebo-controlled Crohn’s disease trial results demonstrated that specific blood immune markers associated with immune activation and mucosal healing increased with SSI treatment and SSI response/remission. The company says it plans to initiate a follow-on clinical trial in Crohn’s disease later in 2017 to confirm the value of these blood immune biomarkers in predicting and monitoring response to SSI therapy. Story 2 The National Research Council of Canada (NRC) and Toronto-based Centre for the Commercialization of Antibodies and Biologics (CCAB) are teaming up to advance new innovative therapies discovered out of the University of Toronto. Through this innovative collaboration between government, industry, and academia,  the NRC and the (CCAB) have over the past year already put in place over $1M in collaborative agreements to produce and test therapeutic antibodies discovered at the University. CCAB is a business development and commercialization engine whose mission is to translate UofT’s large portfolio of early stage biologics into high-value assets and products. To this purpose, CCAB has partnered with NRC to biomanufacture and test hundreds of antibodies. With this announcement, the collaboration continues to grow and now leverages NRC’s three programs in Human Health Therapeutics: 1. Biologics and Biomanufacturing: producing biologics, testing their ability to fight solid tumours, and determining their biomanufacturability; 2.  Therapeutics Beyond Brain Barriers: determining if specific antibodies are able to cross the blood-brain barrier, target and fight brain cancer; And 3. Vaccines and Immunotherapeutics: determining if specific antibodies are able to modulate the immune system so that it finds and destroys cancer cells.  As cancer treatment evolves rapidly toward more effective molecules, including single-domain and bi-specific antibodies, antibody-drug conjugates, and immunotherapies, these types of medicines, also called biologics, are able to specifically target cancer cells and in some cases, recruit the body’s immune system to help destroy them. The goal of the collaboration is to identify the most promising antibodies, and increase their value by generating data that effectively de-risks each asset. CCAB says its objective is to then licence lead antibody candidates to seed newly formed Canadian biotechnology companies.  These new Canadian start-ups will, in turn, advance these molecules toward clinical trials in patients.  With several biotechnology companies already participating and benefitting from these programs, the collaboration between CCAB and NRC is clearly set to catalyze the country’s biotech sector and generate promising new cancer treatments for Canadians. Alexion licenses Arbutus’ LNP delivery technology In business news, Alexion Pharmaceuticals has negotiated a license to use Vancouver-based Arbutus Biopharma’s lipid nanoparticle (LNP) delivery technology for one of its rare disease messenger RNA (mRNA) therapeutic candidates. As part of the deal, Arbutus will earn $7.5 million upfront from Alexion and potentially another $75 million in development, regulatory, and commercial milestones, plus single-digit sales royalties. Arbutus will also carry out technology development and provide manufacturing and regulatory support for the Alexion mRNA candidate. Arbutus Biopharma itself is currently focused on developing a cure for chronic hepatitis B virus (HBV) infection. Dr. Mark J. Murray, Arbutus’ President and CEO said this transaction with Alexion illustrates the value of his company’s LNP platform, which he believes has broad potential to deliver mRNA and gene editing therapeutics. He adds that Arbutus is receiving significant interest from companies that require access to the LNP platform to enable their own development programs BELLUS Health sells Thallion Pharmaceuticals subsidiary to Taro Pharmaceuticals BELLUS Health Inc. reports it has entered into a share purchase agreement with Taro Pharmaceuticals Inc. (Taro) for the sale of its wholly-owned subsidiary Thallion Pharmaceuticals Inc. as well as the rights to the drug candidate Shigamab™. According to Bellus, the asset, Shigamab™, is a monoclonal antibody therapy being developed for the treatment of Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (STEC) (sHUS), a rare disease which principally affects the kidneys and often leads to acute dialysis, and in certain cases chronic kidney disease and death, primarily in children. Pursuant to the sale, Taro is acquiring all issued and outstanding shares of Thallion for a potential total consideration of CA$2.7 million, consisting of an upfront payment of CA$2.3 million and a potential future payment of CA$0.4 million contingent upon the completion of a pre-established milestone event, expected to occur within 24 months of the closing of the transaction. Additionally, BELLUS Health will receive a portion of certain post-approval revenues related to the Shigamab™ program. Story 5 In our feature story this week, on March 21st, the federal Liberal government officially presented their second budget since coming to power. In our feature story this week, on March 21st, the federal Liberal government officially presented their second budget since coming to power. In the months leading up to its release, this budget was of course billed by the Feds as the Innovation Budget, and certainly at first glance there are a few initiatives where spurring innovation or forming an Innovation Agenda for Canada is its goal.  But has this Budget measured up to its promise? Has the government truly delivered with Budget 2017 an Innovation Agenda to hitch our wagons to? We have with us today, Andrew Casey, CEO and president of BIOTECanada, the national organization that represents health care, agricultural, food, and research groups involved in biotechnology to find out if government has hit the mark or missed it in terms of delivering on its innovation mandate. Hello Andrew and welcome to the show. 1. Going into Budget 2017, there were many surveys, consultations and open dialogue between Government and industry, on what we wanted to see from this Innovation Agenda budget. Straight to point, did Budget 2017 live up to its hype? For BIOTECanada, what was on your wishlist- what were you hoping to see in the budget? What were the asks on the wish list that were answered, and which asks weren’t? Let’s look deeper, in our analysis of the investment summary, the biggest program of interest seems to be the $950 million “super clusters” fund, that will be an open competition in 2017 across six innovation industries, with biotech of course being one these industries. Like with most such initiatives there is of course some worry that biotech as one of the six, may not get it proverbial portion of the pie, does BIOTECanada see it this way, or do they feel that our industry can benefit from this fund? 5. In terms of strengthening science in government, Budget 2017 proposes to establish a new chief science advisor for Canada, what should we expect to see from the creation of this new role? There was also $6 million earmarked for stem cell research, and organizations in that field like the Stem Cell Foundation and other stakeholders seemed satisfied in that commitment, but on a grander scale, does that really compare with other leading jurisdictions in the field? Are those funds enough to capitalize on Canada’s strengths in this field? What we found interesting as well in Budget 2017 was the proposal of a new procurement program, called Innovative Solutions Canada, modeled on the SBIR (Small Business Innovation Research Program) in the U.S. with $50 million to go into this program. For comparison sake, in Fiscal Year 2016, the NIH’s SBIR and STTR programs south of the border will invest over $870 million into health and life science companies, so how does our commitment stack up? Is it a good first step into this arena? Glancing at the investment summary, we also noticed that basic research programs, such as the Tri-Councils, were not mentioned. Why do you think that was? Finally, another industry ask is always around supporting venture capital and Budget 2017 proposes $400 million over the next three years for a new Venture Capital Catalyst Initiative. Is this separate from the $400 million Venture Capital Action Plan from year’s past? Were there any other examples where existing funding and credits were maintained or even expanded upon in Budget 2017. Well Andrew, thank you for joining us today on our show and for your breakdown of #BUDGET2017, it’s always a pleasure for us to talk with you and get your insights on key industry topics.  

Ahead on Biotechnology Focus Radio : Bellus Health back in the game with a new therapeutic asset, BC Cancer Agency scientists make two breakthrough discoveries, and RepliCel Life Sciences gets by with a little help from its friends. We have this and more in store for you on this week’s show. Welcome to another episode of Biotechnology Focus Radio. I’m your host Shawn Lawrence, here to give you a rundown of this week’s top stories on the Canadian biotech scene.   Our first story this week takes us to CALGARY, AB where a team of Canadian physicians and researchers are believed to be the first in the world to have used gene therapy to treat a patient with Fabry disease, a rare inherited enzyme deficiency that can damage major organs and shorten lifespan. Specifically, people with the disease have a gene called GLA that doesn’t function as it should; as a result their bodies are unable to make the correct version of a particular enzyme that breaks down a fat called Gb3. A buildup of Gb3 can lead to problems in the kidneys, heart and brain. In their experimental trial, the researchers led by Dr. Aneal Khan, a Alberta Health Services medical geneticist and member of the Alberta Children’s Hospital Research Institute, Cumming School of Medicine, University of Calgary collected a quantity of a Fabry patient’s own blood stem cells then used a specially engineered virus to augment those cells with copies of the fully functional gene that is responsible for the enzyme. The altered stem cells were then transplanted back into the patient on Jan. 11, 2017. While Dr. Khan says it’s too soon to say whether this therapy will ultimately be a long-term treatment for the disease, based on the team’s success in animal trials, he is hopeful it will be a beneficial to patients Dr. Jeffrey Medin, a researcher with the Medical College of Wisconsin and the project’s principal investigator, adds that the trial is a major step forward in treating inherited genetic diseases in adults. The treatment, which has been approved by Health Canada for experimental purposes, is also believed to be the first trial in Canada to use a lentivirus in gene therapy. In this case, the specially modified virus was stripped of its disease-causing capability and augmented with a working copy of the gene that’s responsible for the missing enzyme. The project is being funded by the Canadian Institutes of Health Research and the Kidney Foundation of Canada. The Queen Elizabeth II Health Sciences Centre in Halifax and the University Health Network in Toronto are also recruiting people with Fabry disease for the trial. In R&D news, a team of BC Cancer Agency scientists has made two exciting drug discoveries that could potentially allow for new approaches to target various cancers more specifically, through the exploitation of mutations found only in cancer cells and not normal cells. The first discovery, which has already led to a clinical trial, exploits the inability of BRCA1/2 deficient cancers to repair their own DNA. The second discovery is of a drug-like molecule that can alter the way cells translate genetic information into proteins. Both discoveries were made by Dr. Sam Aparicio, head of the Department of Breast and Molecular Oncology, and his research team at the BC Cancer Agency.The first success in this area is a discovery published in Nature Communications, where Dr. Aparicio’s team has discovered that the drug, CX-5461, originally developed for cancers of the blood and lymph system, can be repurposed as a drug treatment for breast cancer. Still early in its clinical development life cycle, CX-5461 has been shown through Dr. Aparicio’s latest work, to bind to the DNA of certain regions of the genome causing it to fold up and interrupt the DNA copying process. Thus, the compound is selectively active in tumours from patients with mutations in the BRCA1/2 gene, known to cause a strong familial predisposition to breast cancer, and account for approximately 15 per cent of the population with the disease. The study is currently in Phase 1 of a multi-centre clinical trial coordinated by Canadian Cancer Trials Group, which began in June of 2016. Phase two will accept even more patients to determine whether the activity found through preclinical studies is reflected in responses in patients. Both Dr. Aparicio and Dr. Karen Gelmon, senior scientist, medical oncologist and the clinical trial lead for the study add that if the trial is successful, they then hope to expand testing to other types of cancer in the near future. In addition to the CX-5461 findings, a second paper published in Nature Communications communicates the discovery of a different prototype drug, a compound called ‘T3’, engineered to alter the way that cells translate DNA, through splicing of RNA, into proteins. According to the researchers, this small, yet highly-potent drug-like molecule, currently in lab-testing, is being used to understand how different breast cancer cells might be susceptible to having RNA splicing interrupted. The drug molecule interferes with the molecular machinery that stiches gene sequences together to make fully functional proteins. Mutations in RNA splicing genes and defects in splicing have been found in diverse cancers, including breast cancer. The prototype drug molecules are allowing Dr. Aparicio and his team to seek out situations where cancer cells are uniquely susceptible to interference with RNA splicing. As alluded to, both drug development studies are currently centered in breast cancer treatment, but hope to expand to other types, including prostate and ovarian. Dr. Aparicio and his team’s work was supported with strategic funding from the BC Cancer Foundation. In Business new, two European firms are teaming up with Vancouver based regenerative medicine company, RepliCel Life Sciences Inc.to assist RepliCel in getting its commercial-grade RCI-02 dermal injector prototypes manufactured and tested. One of the partnering firms, AMI, is an Austrian manufacturer of medical technology based near the shores of Lake Constance, within easy reach of Germany and Switzerland. AMI develops, manufactures and distributes their medical products throughout the world. All of them are made according to the highest quality standards and enable doctors to take even better care of their patients. The second partner, Art of Technology (AoT), is based in Zurich Switzerland and is an independent contract developer specializing in the design, development and miniaturization of complex customer specific electronic devices and embedded systems for use in industrial, medical and space applications. The RCI-02 injector itself was designed with input from dermatologists, industrial designers, and electronic and medical device engineers to improve the delivery of a variety of injectables in a controlled, precise manner, removing the risks and uncertainties of injection outcomes currently resulting from manually operated, single-needle syringes. According to RepliCel president and CEO, Lee Buckler, it is the world’s first motorized injection device with programmable depth and volume, a built-in Peltier element for pre-injection anaesthetising, and interchangeable needle head configurations. It is designed to deliver a variety of injectable substances including cells, dermal fillers, drugs or biologics intradermally (dermis), subcutaneously (fat) or intramuscularly (muscle) via an array of needle configurations ranging from a single needle to a 16 needle configuration (4×4) on one head. Buckler adds that the execution of these agreements covers what RepliCel believes to be the final stages needed to prepare RCI-02 for a market authorization application in the form of a CE mark in Europe. The company hopes to have the device ready for a CE mark application and in the hands of a licensing and commercial partner next year. Our next story takes us to the Maritime provinces where the Terry Fox Research Institute is investing $5-million in support of New Brunswick researchers and their colleagues at other cancer centres in Canada to study how new precision medicine tools could improve, and potentially save the lives of patients diagnosed with the incurable cancer of the blood and bone marrow, known as multiple myeloma. The initiative is known as the Multiple Myeloma Molecular Monitoring (M4) Study, and Dr. Tony Reiman, a medical oncologist and professor at the University of New Brunswick, will lead the team, which comprises researchers and clinicians at multiple sites including Vancouver, Calgary, Toronto and Montreal. Dr. Reiman says that he hopes the five-year study will result in game-changing new approaches to identifying, treating and monitoring the disease in patients, including those who are at high risk of relapse. His team in Saint John will organize all the participating centres as well as conduct its own research and receive and bank specimens (blood and marrow) from the 250 myeloma patients that will participate in the project. Additionally, M4 study team members will use tests based on advanced techniques like immunoglobulin gene sequencing, multiparameter flow cytometry, PET scans, circulating tumour DNA analysis, and novel drug resistance assays to evaluate the patient specimens and other biosamples. Principal investigators at the partner sites are: Drs. Donna Reece and Suzanne Trudel, Princess Margaret Cancer Centre; Dr. Nizar Bahlis, University of Calgary; and Dr. François Bénard, BC Cancer Agency. Patients will be recruited by the study investigators at their own sites. Principal investigators Drs. Reece and Trudel (PM) explain their role in M4 study in the following audio. BrainStorm Cell Therapeutics Inc., a HACKENSACK, N.J.- based company developing adult stem cell technologies for neurodegenerative diseases, has signed an agreement with CCRM in the hopes of furthering its market authorization request for NurOwn®.  For our new listeners, CCRM is a Toronto-based company focused on developing and commercializing regenerative medicine technologies, specifically cell and gene therapies. Through the agreement, CCRM will help Brainstorm explore opportunities to access Health Canada’s early access pathway for treatment of patients with Amyotrophic Lateral Sclerosis (ALS).  If NurOwn® qualifies for Health Canada’s “Notice of Compliance with Conditions” pathway, it could be authorized in Canada for distribution in early 2018. Through the agreement, the company will work Patrick Bedford, manager of clinical translation and regulatory affairs at CCRM. Stacey Johnson (@msstaceyerin) , director, communications and marketing at CCRM and editor of Signals Blog discussed this deal recently via her regular Right Turn column Be sure to check it out at http://www.signalsblog.ca/right-turn-new-stem-cell-product-for-als-seeking-approval-in-canada/. For our final story, nearly a year since it’s failed KIACTA™ Phase 3 trial and subsequently being forced into pulling the plug on its KIACTA program, BELLUS Health is back from the brink as the Montreal-based company announced a new partnership and licensing deal with The NEOMED Institute to take over the development and commercialization activities for a potential new treatment for chronic cough. According to Bellus stakeholders,, this is a transformative transaction as this exclusive worldwide license agreement adds to the company’s pipeline a potentially best-in-class drug candidate, BLU-5937, an asset which was formerly known as NEO5937.  Its development through  the P2X3 antagonist program was initiated by AstraZeneca scientists in Montreal, and assigned to NEOMED in October 2012 when the NEOMED Institute was first launched. It was selected as a drug candidate to advance towards the clinic based on development efforts and extensive pre-clinical work in chronic cough done at NEOMED. According to Roberto Bellini, president and CEO of the company, the drug now going by its new name BLU-5937  will be a core focus of BELLUS’s drug development efforts. About the condition, Chronic cough is a cough that lasts eight weeks or longer and significantly impacts quality of life, with significant social (exclusion, embarrassment, difficulty speaking), physical (sleep deprivation, rib fracture, vomiting) and psychosocial (anxiety, depression) repercussions. It is estimated that in the U.S. alone, more than 2.7 million patients suffer from chronic cough that is not controlled by currently available medications. How BLU-5937 works to treat it, is it acts on a clinically validated target in the chronic cough pathway, the P2X3 receptor. Both the company and NEOMED believe BLU-5937 has the potential to become a best-in-class treatment option because of its superior potency and selectivity for the P2X3 receptor. These properties suggest BLU-5937 will be effective and less likely to cause a problematic side effect seen with less-selective drugs: taste disturbances that are significant enough to affect drug compliance. Under the terms of the agreement, BELLUS Health will pay NEOMED an upfront fee of $3.2 million, consisting of $1.7 million in cash with $1.5 million worth of BELLUS Health common shares (Approximately 5,802,177 shares). NEOMED will also be entitled to receive a royalty on net sales-based revenues. Additionally, in lieu of milestone payments, a certain portion of all other revenues received by BELLUS Health from BLU-5937 will be shared with NEOMED according to a pre-established schedule whereby the shared revenue portion decreases as the program progresses in development. Well that wraps up another episode of the Biotechnology Focus Podcast. We hope you enjoyed it. Be sure to let us know what you think, and we’re also always looking for story ideas and suggestions for future shows, and of course we’d love to hear from you as well, simply reach out to us via twitter @biotechfocus, or by email at the following email address  press@promotivemedia.ca. And remember, you can also listen to past episodes online via our podcast portal at www.biotechnologyfocus.ca . For all of us here at Biotechnology Focus, thanks for listening

Bellus Health is left reeling as its lead drug Kiacta fails its Phase 3 clinical study, Vancouver based QLT inks a merger deal with Aegerion Pharmaceuticals and looks to a fresh new start, and Biotechnology Focus relaunches its Hot Button Issue Survey. We have this and more on this weeks show! Show Notes: We kick things off this week with some bad news on both the business and the clinical trial front with BELLUS Health the rare disease drug development firm reporting top line results from its Phase 3 study of KIACTA™ (eprodisate) as a treatment of AA amyloidosis. The disease is characterized by secondary to severe chronic inflammation or infection leading to the formation and deposition of amyloid fibrils in organs, often resulting in end-stage renal disease and death. Currently there are no therapies available that target the disease directly. According to company CEO Roberto Bellini, KIACTA™ failed to meet its primary efficacy endpoint in slowing renal function decline. The news, announced on June 20, was somewhat surprising to both the company and its investors. Shares for the company on the TSE under the trade symbol BLU plummeted, going from $2.42 on June 17, to around $0.39 on the day of the announcement, holding at .40 cents today. Many investors had rallied to the company over the past year due to the drug being in later stages of clinical trial development. Moreover, the science seemed sound as in earlier studies, KIACTA™ was shown to significantly delay the disease.  In both earlier studies and even in the failed trial, it was found to be safe and well tolerated over treatment periods of greater than four years. The confirmatory Phase 3 study of KIACTA™ was a global study across more than 70 sites in more than 25 countries that randomized 261 patients to receive either 800mg dose of KIACTA™ twice daily or placebo. The  study was an event driven study that lasted five years meeting its completion target of 120 patient events linked to the deterioration of kidney function in January 2016. The company added that further analysis of the data is ongoing, and a more detailed data set of the KIACTA™ Phase 3 study will be presented July 6 at the XV International Symposium . Roberto Bellini, president and CEO of the company adds that while Bellus is disappointed that the Phase 3 study did not meet the primary efficacy endpoint, the full data set will be assessed to determine the best path forward. The company says in the aftermath of the failed trial, it will continue working on a number of other projects in its portfolio,  including its study of KIACTA™ as a treatment for sarcoidosis (set to enter Phase 2 trials), clinical development of Shigamab™ as a treatment for STEC-related Hemolytic Uremic Syndrome (sHUS), and the company’s research-stage project for AL amyloidosis. We go from negative news to the more positive, as QLT Inc., once upon a time Canada’s hottest biotech company, and a company long-entrenched as a in the BC- biotech community inking a strategic merger agreement with Cambridge-based Aegerion Pharmaceuticals, Inc. The proposed deal has been approved by the board of directors of both companies, and is expected to close late in the third quarter or during the fourth quarter of 2016. Upon closing, QLT says it plans to change its name to Novelion Therapeutics Inc. adding that its common shares will trade on the NASDAQ Global Select Market and the Toronto Stock Exchange. QLT’s current market cap is approximately $110 million (CDN) and Aegerion has a market cap of approximately $70 million (CDN) giving the new combined company a market value of approximately $180 million. This isn’t QLT’s first attempt to merge with another company, having been thwarted in the past in prior merger arrangements with Endo International, Auxilium Pharmaceuticals and InSite Vision. The planned merger with Endo International was terminated in October 2014, and likewise, Auxilium had also been carrying out plans to merge with QLT but chose instead to be bought by the aforementioned Endo International in a separate deal valued at $2.6 billion. Likewise, last year, QLT and InSite announced a merger, but that deal fell through after InSite changed its mind and accepted a higher merger offer from Sun Pharmaceutical Industries. This time QLT won’t be left at the alter so to speak, and likewise both companies under the Novelion Therapeutics Inc. banner will get a much needed rebrand and fresh start. The new company will also have quite a diversified portfolio consisting of Aegerion’s two commercially branded products, Juxtapid® (lomitapide) capsules and Myalept® (metreleptin), and QLT’s QLT091001 (Zuretinol Acetate or Zuretinol), a Phase 3-ready Ultra-Orphan Fast Track and Orphan Drug designated asset being developed for the treatment of Inherited Retinal Disease caused by underlying mutations in RPE65 or LRAT genes (IRD), which indication comprises Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP). Aegerion’s CEO, Mary Szela, will serve as CEO of Novelion following the close of the transaction. Additionally, an investor syndicate comprised of both new investors and existing shareholders of both companies has  committed to invest via a private placement approximately $22 million in QLT. The investment will be funded prior to the transaction close and is expected to provide Novelion with additional capital to support future operations and the potential opportunity for targeted business development initiatives. In futher business news, TVM Life Science Ventures VII a venture capital fund domiciled in Montréal, Québec, has closed the fund’s eleventh investment, establishing Mediti Pharma Inc., a company based in Montréal, Québec. The new company is developing a Phase 2 ready compound, MP-101, originally discovered by Eli Lilly and Company for the treatment of Alzheimer’s disease (AD) psychosis. The behavioral symptoms associated with AD psychosis, include hallucinations, delusions and aggression. The company is managed by CEO Dr. Ivan Shaw, formerly with Merck Frosst, Aptalis and Actavis and neurobiologist and experienced drug developer and CFO Mark Cipriano, a Boston-based highly experienced and networked executive. As for the fund itself, and its initial association with the drug, it comes about as part of a unique arrangement between TVM Capital Life Science and numerous limited partners, which includes Eli Lilly and Company.  The goal of the fund is to finance and access innovation while managing risk and sharing reward. Staying in Montreal, on the clinical trial front Montreal InVivo , the city’s economic development organization with a focus on life sciences and health technologies (LSHT) sector. is partnering with Canadian Clinical Trails Coordinating Centre(CCTCC) to enhance Canada's clinical research capabilities. The partnership will result in the addition of Quebec clinical trial investigators "data from Montreal Goes Clinic to the Canadian ClinicalTrials Asset Map (CCTAM) and real-time updates down the line. The Montreal Goes Clinic itself is an initiative by Greater Montreal's life sciences"; cluster that aims to make the region a world-class centre of expertise in early stage clinical trials.  The goal of this initiative is to improve Greater Montreal's business environment by helping pharmaceutical, biotech, contract research organizations (CRO's) and medical device companies perform high quality clinical trials and run clinical proofs-of- concept, thus  increasing patient access to new treatments and improving medical practices by allowing clinicians to work with technologies of tomorrow and the best equipment. Frank Béraud, CEO of Montréal InVivo adds that the portal will create more visibility for Quebec's researchers and investigators throughout Canada, and will also showcase the province's capabilities in clinical research. Dr. Shurjeel Choudhri, senior vice president and head, Medical and Scientific Affairs Bayer Inc. and the current Chair of the CCTCC Executive Committee adds that the CCTAM is a great example of the collaboration of multiple stakeholders from across Canada, including representatives from the Federal and Provincial governments, industry, the Canadian Institutes of Health Research and HealthCareCAN. He calls the addition of clinical investigator data from Montreal Goes Clinic an important step towards making the CCTAM a truly comprehensive inventory of Canada's clinical research assets. If you could have a face-to- face conversation with government to discuss the life science industry, both the good and the bad what would you say? A number of years ago Biotechnology Focus used to run a special Hot Button Issue survey which gave our readers the opportunity to engage with government to get their concerns before the right people and have their voices heard. Well, with the Justin Trudeau government coming up to its ninth month in office, we thought the timing was right to do it all again. The survey kicked off yesterday and will run to July 15, 2016. Similar to our past “Hot Button” issue surveys, we want your feedback on such things as regulatory policy including reimbursement of new technologies, funding challenges, intellectual property protection, the state of the industry and much more. This survey is open to everyone in the industry, from the business sector, to research institutions, and at all levels, essentially, if your field is biotech, bioscience or life science in general we want to hear from you. This already is vibrant industry, with strong representation at major research and knowledge translation institutions, a large base of Canadian biotech SMEs and MMEs, and we’re home to many of the world's largest and leading pharmaceutical companies. Moreover, the timing for this survey couldn’t be better as the Federal government as mentioned in last week’s podcast has just launched the “Innovation Agenda”, an action plan to both redesign and redefine how we as a nation support innovation and growth. They have embarked on this Innovation Agenda in partnership and coordination with the private sector; provinces, territories and municipalities; universities and colleges; and the not for-profit sector and they have also already taken the first steps in this plan already with Budget 2016, providing support for health research, genomics, regenerative medicine, brain research and drug development and committed $800 million to support innovation networks and clusters. So there’s obviously lots that government is doing right to make Canada a friendly environment for our industry, but can we do more? Canada’s Minister of Innovation, Science and Economic Development Navdeep Bains has asked us all to step up and voice our opinions, to help further shape the future of Canada’s knowledge based economy. And our Hot Button Issue survey is your chance to do that! Your answers will be featured in a special high profile issue that will be poly-bagged with our sister publication Canadian Government Executive magazine and sent to Deputy Ministers, Assistant Deputy Ministers, Cabinet, Directors and Generals, working in Health Canada, Industry Canada, Agriculture & Agri-Food, Foreign Affairs & Internationals trade, the Privy Council as well as other public sector executives in federal and provincial departments. So here is your chance to help influence the Innovation Agenda. And remember, by taking only a couple of minutes to complete our survey, you’re helping us grow Canada’s knowledge-based economy, one answer at a time. You can access the survey by clicking the link below this podcast. That wraps up this weeks show, you can find us online at www.biotechnologyfocus.ca. Likewise, we’re always looking for feedback, story ideas and suggestions so we’d love to hear from you. Simply reach out to us on twitter: @BiotechFocus , email at biotechnology_focus@promotive.net For all of us here at Biotechnology Focus, thank you for listening.

We've hit the double digits, this is Episode 10 of Pixel Sift. If you just tuned in, thanks for joining us and each week we talk video games and video game culture. This week we streamed the show live on twitch.tv/pixelsift so you can watch as well as listen. First up on the show today we talk about the worst players online who ruin the multiplayer for everyone. Riot Games makers of the extremely popular League of Legends, have implemented a new system where the worst players online miss out completely on free loot. Other games such as Hearthstone by Blizzard have opted out of online chat entirely, using emotes and phrases instead. If you are in Western Australia this weekend you can check out the Perth Games Festival, a celebration of WA game dev talent. We spoke to Jon Hayward and Jess Watson from Let's Make Games who organised the Perth Games Festival. It's on the 28th of November 2015 at the Perth Town Hall, and tickets are free. Head to perthgamesfestival.com.au for all the details. Finally for our first in studio interview Kai Ashford-Hatherly, from RW Games joined us and told us all about his new game Bellus Mortem which has just launched on Kickstarter. We asked why they went Kickstarter over other funding methods. You can find us on all the social media sites, Twitter, Facebook, Instagram, Twitch and Steam. Just search for "pixelsift" and you'll find us!

Enemy Khlyen I want to hear from you! Send me your feedback at 1-805-910-7656 or feedback@solotalkmedia.com Welcome everyone. I am so happy that you’ve joined me to discuss Killjoys. What an amazing penultimate episode. I think it was one of the best of the season. This week during my episode discussion I discuss the revelation that Khlyen is actually part of the RAC and how Dutch, Johnny and D’avin’s infiltrat the RAC trying to reach him on level 71. I also talk about Turin’s suspicions of the trio and what part he may play in the future. I touch briefly on what is happening to Alvis back on Westerley and they war that is brewing. And of course I talk about the revelation that Khlyen is Level 6. So please join me as I discuss the ins and outs of “Enemy Khlyen” As always, my episode discussion is followed by some great feedback contributors from listeners. You can purchase this television series or any other series on DVD or Blu-Ray through Amazon. As an Amazon Associate I earn from qualifying purchases. Please click if you are in the  USA or Canada Links mentioned in the show. Interview with creator Michelle Lovretta Interview with Bellus, Pree and Fancy Lee My […]

Jordan Salcito is one of the hottest young wine experts in America. She chats with Cherry Bombe’s Claudia Wu about working as beverage director of the Momofuku restaurant group; launching Bellus, her indie wine label; and studying to become a master sommelier. Tune in to hear this and more. Wine not?

Jordan Salcito comes into the studio on this week’s In the Drink to speak to us about her position as Beverage Director for David Chang’s famous Momofuku restaurants. She is also a sommelier and entrepreneur living in New York City. After college, Jordan traveled through Italy, moved to New York City and began working in restaurants. She earned a scholarship to attended culinary school at Johnson & Wales University, then moved back to New York to cook at Daniel Boulud’s flagship restaurant, Daniel. In 2006, Chef Boulud granted her the opportunity to cook with him at the La Paulée de Nieges. From that moment, she knew that she wanted to spend her life working with wine. Jordan has worked in some of New York’s most esteemed dining rooms, including at Eleven Madison Park (where she was part of the James Beard Award-winning team for Outstanding Wine Service), Daniel, Gilt at the New York Palace, and Crown, where she built and managed the wine program during its inaugural year. She has also worked harvests in Burgundy since 2006 at esteemed wineries such as Domaines Dujac, Mugneret-Gibourg, De Montille, Comtes Liger-Belair, and de l’Arlot, as well as harvests in Montalcino and Patagonia. In 2011, she launched Bellus Wines. Her first release, the 2007 “Girasole,” from Montalcino, donates a percentage of proceeds to female entrepreneurs through The Tory Burch Foundation. Her second release, the 2011 “Les Roches Soeurs,” is a collaboration with Alix de Montille of Meursault. Accolades include the Advanced Diploma from the International Wine Center, and an Introduction to Winemaking course at UC Davis. She is a Master Sommelier Canditate in the Court of Master Sommeliers. Jordan’s expertise has landed her roles as Rachael Ray’s “Wine Buddy”; PBS Vine Talk’s co-host; and one of Gilt Taste’s sommelier panelists. She and Bellus have been featured in publications such as Food & Wine, Allure, Travel + Leisure, WWD, Martha Stewart Radio, CNN.com, The Huffington Post, Every Day with Rachael Ray, USA Today, Women’s Wear Daily, and The Food Republic. Tune-in to learn how Jordan supervises a large team at Momofuku restaurants, how she moved from a career as a writer to becoming a sommelier, and even what it’s like to live in the same house with another wine enthusiast! This program has been sponsored by Brooklyn Slate. “Our job is to bring to light in the most honest way, the experience of serving wine to our guests.” [27:30] “I try to tailor each guest’s experience. I always recommend going to see one of the larger producers, and that’s where you have this amazing snapshot.” [29:20] — Jordan Salcito on In the Drink